18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: Is a single standardized uptake value threshold approach appropriate?

Journal of Nuclear Medicine

Volumn 47, Issue 11, 2006, Pages 1808-1812

  Biehl, Kenneth J ^a   Kong, Feng Ming ^b   Dehdashti, Farrokh ^c,d   Jin, Jian Yue ^e   Mutic, Sasa ^a   El Naqa, Issam ^a,d   Siegel, Barry A ^c,d   Bradley, Jeffrey D ^a,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

^e HENRY FORD HOSPITAL   (United States)

Author keywords

18F FDG PET; Lung cancer; Threshold

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARDIZATION; TUMOR DIAGNOSIS; TUMOR VOLUME; COMPUTER ASSISTED RADIOTHERAPY; IMAGE PROCESSING; INSTRUMENTATION; LUNG TUMOR; METHODOLOGY; NEOPLASM; ONCOLOGY; PATHOLOGY; RADIATION DOSE; STATISTICAL MODEL;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LINEAR MODELS; LUNG NEOPLASMS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34447256267     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 1999;213:530-536.
2. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879-892.
3. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of nonsmall-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261.
4. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526-533.
5. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
6. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285-1292.
7. Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol. 1996;19:416-421.
8. Ichiya Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med. 1996;10:193-200.
9. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:78-86.
10. Erdi YE, Rosenweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002;62:51-60.
11. 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 1998;19:167-177.
12. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-118.
13. 18FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys. 2002;52:339-350.
14. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317-324.
15. 18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593-597.
16. Paulino AC, Thorstad WL, Fox T. Role of fusion in radiotherapy treatment planning. Semin Nucl Med. 2003;33:238-243.
17. 18F- deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys. 2001;49:1249-1257.
18. 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342-1348.
19. 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers [in French]. Cancer Radiother. 2005;9:304-315.
20. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:1016-1023.
21. Brianzoni E, Rossi G, Ancidei S, et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging. 2005;32:1392-1399.
22. Erdi Y, Mawlawi O, Imbriaco M, et al. Volume determination for metastatic lung lesions by adaptive PET image thresholding. Cancer. 1997;80:2505-2509.
23. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353-359.
24. Fernando S, Kong FM, Kessler M, et al. Using FDG-PET to delineate gross tumor and internal target volumes. J Radiat Oncol Biol Phys. 2005;63(suppl):S400-S401.
25. Caldwell CB, Mah K, Skinner M, Danjoux CE. Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET. Int J Radiat Oncol Biol Phys. 2003;55:1381-1393.
26. Black QC, Grills IS, Kestin LL, et al. Defining a radiotherapy target with positron emission tomography. J Radiat Oncol Biol Phys. 2004;60:1272-1282.
27. Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med. 2004;45:1287-1292.
28. Nehmeh SA, Erdi YE, Pan T, et al. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys. 2004;3:1333-1338.
29. 18F-FDG PET/CT standardized uptake values. J Nucl Med. 2005;46:424-428.
30. 18F] fluoro-D-glucose with positron emission tomography: clinical significance of iterative reconstruction and segmented attenuation compared with conventional filtered back projection and measured attenuation correction. Mol Imaging Biol. 2002;4:294-300.
31. Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294-301.
32. El Naqa I, Low DA, Bradley JD, Vicic M, Deasy JO. Deblurring of breathing motion artifacts in thoracic PET images by deconvolution methods. Med Phys. 2006;33:3587-3600.